×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

Buy Pfizer Before the Smart Money Catches On to the Plot

Wednesday, February 9, 2022 | Chris Markoch
Buy Pfizer Before the Smart Money Catches On to the Plot

The sell-off in PFE Stock After Earnings is Based on Quick Trigger Fingers 

Pfizer (NYSE:PFE) stock is dropping in mid-day trading after the company delivered a mixed earnings report. The company delivered a strong beat on earnings per share of $1.08 compared to the analysts forecast for 86 cents per share. But it was the revenue number that has investors pulling back. 

Pfizer’s Q4 revenue came in slightly below the forecasted $24.12 billion with $23.84 billion. However, that also meant that the company also came in below the full-year forecast by about half a billion dollars.  

But is that a reason for PFE stock to be down 4.5%? I don’t think so and believe that once the smart money takes a closer look at Pfizer, the stock is going to climb. 

It Wasn’t a Bad Report 

Even though Pfizer came in short on revenue expectations, it still delivered record revenue of over $80 billion. Furthermore, the company gave full-year guidance for 2022 of $98 - $102 billion. And the earnings story is even better. Pfizer is forecasting full-year EPS between $6.35 and $6.55. At the low end of that guidance that would be a 68% increase from the total of $3.76 the company delivered for full-year 2021.  

I suppose if analysts were to nitpick, they would point out that the company had lackluster sales in its internal medicine and hospital segments. In fact, when you take out the company’s Covid-related revenue streams, revenue fell 2%.  

But at this point, it seems that investors are jumping to a pre-determined conclusion. Unless Pfizer beat on both the top and bottom lines it was going to get knocked down.  


That’s not a compelling argument to us. And after plunging below $50 per share it looks like the stock is beginning to stage an inner day comeback.  

On the Forefront of the Future of Medicine 

Of course, the major reason that Pfizer has generated record profit and revenue is its Covid-19 portfolio of vaccines and therapeutics. In fact, the company said it expects to generate more than $50 billion between its Covid-19 vaccines and Paxlovid, its antiviral coronavirus treatment pill.  

Any discussion of the company’s Covid-19 vaccine stirs strong emotions. One reason for this is the use of mRNA technology in the development of the vaccine. It’s true that the Pfizer vaccine which it developed with BioNTech (NASDAQ:BNTX) as well as the Moderna (NASDAQ:MRNA) vaccine are the first examples of mRNA being used in a vaccine.  

But if the company’s first mRNA vaccine was designed to treat rare genetic conditions, I suspect the public reaction would be different. And yet, that’s exactly what Pfizer is eyeing for its next application of messenger RNA. The company is partnering with Beam Therapeutics to use mRNA to treat rare genetic diseases of the liver, muscle, and central nervous system.  

And this is the plot that we believe the analysts are missing. Today, Pfizer is profiting from Covid-19 for sure. But the vaccines have shown that mRNA technology can be used effectively. And that opens the door for “customizable medicine” that has always been the holy grail.  

Analysts Still Love PFE Stock 

In the month heading into earnings, Pfizer stock had received multiple price target increases. And many of those targets are much higher than the $58.56 consensus price target that the stock had going into earnings. Typically, the weeks after an earnings report is a time for analysts to reassess their opinion. We suspect that other analysts are likely to confirm the bullish outlook for Pfizer. And that would be bullish for PFE stock.  

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Pfizer (PFE)
2.1679 of 5 stars
$52.31-0.2%3.06%12.00Moderate Buy$57.26
BioNTech (BNTX)
1.8952 of 5 stars
$157.50+5.6%N/A2.74Hold$254.57
Moderna (MRNA)
2.3888 of 5 stars
$149.95+5.0%N/A4.41Hold$228.00
Compare These Stocks  Add These Stocks to My Watchlist 

Should you invest $1,000 in Pfizer right now?

Before you consider Pfizer, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.

While Pfizer currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:


Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastSpot Opportunities Even When Disaster Strikes

Today Kate sits down with repeat guest Andrew Chanin, Co-Founder and CEO of ETF manager ProcureAM. Andrew shares the story behind the launch of the Procure Disaster Recovery Strategy ETF (FEMA).

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.